Holen Sie sich die Stockscreener-App
63.21
1.59%
0.99
Handel nachbörslich:
63.04
-0.17
-0.27%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$62.22
Offen:
$62.22
24-Stunden-Volumen:
3.19M
Relative Volume:
0.65
Marktkapitalisierung:
$24.33B
Einnahmen:
$4.66B
Nettoeinkommen (Verlust:
$836.30M
KGV:
30.20
EPS:
2.093
Netto-Cashflow:
$1.08B
1W Leistung:
+2.12%
1M Leistung:
-7.18%
6M Leistung:
-4.75%
1J Leistung:
+5.65%
1-Tages-Spanne:
$62.10
$63.30
1-Wochen-Bereich:
$60.57
$63.68
52-Wochen-Spanne:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Firmenname
Dexcom Inc
Sektor
Branche
Telefon
(858) 200-0200
Adresse
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
63.21 | 23.95B | 4.66B | 836.30M | 1.08B | 2.093 |
ABT
Abbott Laboratories
|
102.30 | 178.75B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
332.30 | 126.97B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.28 | 111.22B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.59 | 93.36B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.19 | 46.73B | 6.07B | 1.06B | 1.34B | 1.8063 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-24 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2026-01-12 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Eingeleitet | Evercore ISI | In-line |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Eingeleitet | Argus | Buy |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-03 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-03-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2023-01-26 | Eingeleitet | Wolfe Research | Outperform |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-15 | Eingeleitet | Bernstein | Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-28 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-01-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-02 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Bestätigt | Piper Sandler | Overweight |
| 2020-05-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-11-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-10-23 | Eingeleitet | Stifel | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-09-12 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Bestätigt | Canaccord Genuity | Buy |
| 2018-07-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
| 2018-05-03 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-04 | Eingeleitet | Goldman | Sell |
| 2018-04-04 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
Nisa Investment Advisors Reduces DexCom Stake by Over 50% - National Today
Nisa Investment Advisors LLC Sells 20,529 Shares of DexCom, Inc. $DXCM - MarketBeat
Aberdeen Group plc Acquires 43,990 Shares of DexCom, Inc. $DXCM - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against DexCom, Inc. (DXCM) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Banque Pictet & Cie SA Raises Stock Holdings in DexCom, Inc. $DXCM - MarketBeat
DexCom Stock Hits Day Low of $62 Amid Price Pressure - Markets Mojo
DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Devon Energy Corp Stock: Strategic Positioning in North American Oil and Gas Amid Market Volatility - AD HOC NEWS
Is DexCom (DXCM) Fairly Priced After Recent Share Price Weakness? - Yahoo! Finance Canada
Mizuho raises DexCom (DXCM) price target to $90 from $78 after earnings beat - msn.com
TD Cowen reiterates DexCom stock Buy rating on margin expansion outlook By Investing.com - Investing.com Australia
TD Cowen reiterates DexCom stock Buy rating on margin expansion outlook - Investing.com India
Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time - Business Wire
SWS Partners Has $3.69 Million Stake in DexCom, Inc. $DXCM - MarketBeat
Compagnie Lombard Odier SCmA Grows Holdings in DexCom, Inc. $DXCM - MarketBeat
DXCM Stock Price, Quote & Chart | DEXCOM INC (NASDAQ:DXCM) - ChartMill
BNY Mellon Large Cap Securities Fund, Inc.'s DexCom Inc(DXCM) Holding History - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages DexCom, Inc. (DXCM) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Pallas Capital Advisors LLC Decreases Stock Holdings in DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. Experiences Revision in Stock Evaluation Amid Market Pressures - Markets Mojo
DexCom Inc. stock rises Tuesday, still underperforms market - marketwatch.com
Soleus Capital Management, L.P.'s DexCom Inc(DXCM) Holding History - gurufocus.com
DexCom Inc (DXCM) Stock Price Down 5.81% on Mar 30 - gurufocus.com
DexCom, Inc. $DXCM Shares Sold by Beacon Investment Advisory Services Inc. - MarketBeat
Dexcom Inc. Stock: Leader in Continuous Glucose Monitoring Faces Evolving Diabetes Care Landscape - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against DexCom, Inc. (DXCM) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Precision Trading with Dexcom Inc. (DXCM) Risk Zones - Stock Traders Daily
Goldman Sachs Initiates Coverage of DexCom (DXCM) with Buy Recommendation - MSN
DAVENPORT & Co LLC Reduces Stake in DexCom, Inc. - National Today
DAVENPORT & Co LLC Has $1.87 Million Position in DexCom, Inc. $DXCM - MarketBeat
DXCM (DexCom) Earnings Power Value (EPV) : $11.42 (As of Dec25) - GuruFocus
DexCom Inc. stock underperforms Friday when compared to competitors - MSN
Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell Shares Are Falling, What You Need To Know - Yahoo Finance UK
DXCM Technical Analysis | Trend, Signals & Chart Patterns | DEXCOM INC (NASDAQ:DXCM) - ChartMill
DEXCOM YoY EBITDA Growth: 52.52% | Significantly Undervalued - GuruFocus
Vanguard (DXCM) amendment shows 0 shares after internal realignment - Stock Titan
DexCom Inc. stock underperforms Thursday when compared to competitors - MarketWatch
DXCM (DexCom) Payments of Debt : $0 Mil (TTM As of Dec. 2025) - GuruFocus
DEXCOM EBIT per Share: $2.73 | Significantly Undervalued - GuruFocus
2026-03-26 | DexCom, Inc. (DXCM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:DXCM | Press Release - Stockhouse
Dexcom Inc. stock surges on Evercore ISI upgrade to Outperform amid CGM market expansion - AD HOC NEWS
Here's why you should hold DexCom stock in your portfolio for now - MSN
DexCom Inc (NASDAQ:DXCM) Presents a Growth Stock Breakout Opportunity - ChartMill
Nordea Investment Management AB Acquires 137,986 Shares of DexCom, Inc. $DXCM - MarketBeat
Assenagon Asset Management S.A. Increases Position in DexCom, Inc. $DXCM - MarketBeat
Dexcom Edges Up on Institutional Buying as CGM Leader Trails $260M Volume Ranks 465th - Bitget
Dexcom Inc. stock rises on Evercore ISI upgrade to Outperform with $90 target amid CGM market moment - AD HOC NEWS
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Dexcom Inc. stock faces spotlight amid continuous glucose monitoring sector evolution and governance - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Is Investigating DexCom, Inc. (DXCM) And Encourages Investors to Connect - ACCESS Newswire
DexCom (NASDAQ:DXCM) Upgraded to "Outperform" at Evercore - MarketBeat
Finanzdaten der Dexcom Inc-Aktie (DXCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):